1st and only HAE treatment indicated for use in pediatrics. Learn more ►
The power to control HAE attacks anytime, anywhere.

Berinert gives your patients the power to treat HAE at the first sign of attack with self-administration, individualized dosing, and valuable support services.

Berinert on-demand — HAE therapy when your patient needs it most Achieving the highest quality and safety standards for Berinert.

"I always have an option to treat my attacks with me."
- Christie

Empower your HAE patients to self-administer at the first sign of attack

HAE attacks can occur suddenly. If patients have no other option besides receiving treatment in a hospital, there could be delays in treatment, or inappropriate or insufficient treatment of an HAE attack. This contributes to the morbidity and social and economic disadvantage associated with HAE. All patients should, therefore, be considered for training in self-administration of on-demand medications.11

WAO Guidelines recommend that all patients with HAE should have an action plan and product available to treat an attack of HAE. In addition, all patients who are provided with on-demand treatment licensed for selfadministration should be taught to self-administer.11

After proper training from a healthcare professional or specialty pharmacy infusion nurse, patients are better prepared to recognize early symptoms and self-administer Berinert at the first sign of an HAE attack. Having a fast and reliable on-demand treatment plan can help put them in control of their HAE and increase their independence.

*Peer supporters are not healthcare professionals or medical experts. For medical questions, patients should contact their physicians.

Berinert features personalized, weight-based dosing for on-demand self-administration treatment that relieves symptoms quickly.

Individualized Dosing, Not Scheduled Prophylaxis

Berinert uses weight-based dosing of 20 IU/kg body weight which ensures an optimized dose of C1-INH during an attack.

Berinert can be administered in 7 minutes, based on a 70-kg (154-lb) patient receiving 20 IU/kg (at a rate of 4 mL/min).

Median time to onset of relief of abdominal or facial HAE is 48 minutes; median time to complete relief is 4.9 hours.* Median time to onset of relief of laryngeal HAE is just 15 minutes; median time to complete relief is 8.4 hours.

*In clinical trial, onset of relief was experienced within 4 hours by 69.8% of treatment group and 42.9% of placebo group. For subjects who did not respond within that time frame, study design allowed for use of rescue medication as follows: placebo for 20 IU/kg body weight Berinert treatment group and 20 IU/kg body weight Berinert for placebo group.

"Within a half hour, or 45 minutes to an hour, the symptoms were completely gone."
- Stephanie

*Peer supporters are not healthcare professionals or medical experts. For medical questions, patients should contact their physicians.

Valuable Patient Support Services

The Berinert Expert Network (B.E.N.®) is a support network for healthcare professionals and patients who depend on Berinert. B.E.N. is the one place for healthcare professionals and patients to access all of the individualized support programs, enabling healthcare professionals to receive support from a single phone call.

B.E.N. can help healthcare professionals and their staff in a variety of areas:

  • Starting a patient on Berinert
  • Insurance coverage, verification, and appeals
  • Access to Berinert patient financial assistance programs
  • Coding and billing assistance
  • Authorized distributor information
  • Information about HAE
  • Connection to the U.S. Hereditary Angioedema Association (HAEA)

B.E.N. provides value-added support for patients to assist them in starting their Berinert and affording their therapy:

  • CSL Behring AssuranceSM insurance gap protection program
  • Patient Assistance program for customers who may not be able to afford their medication
  • Berinert Co-Pay BENefit covers up to $12,000 in out-of-pocket treatment expenses
B.E.N. P.A.L.S. are patients who are Peer Advocates for Learning and Support, just like you and have personal experience with hereditary angioedema and Berinert.

B.E.N. P.A.L.S. patient advocacy program

  • Our B.E.N. P.A.L.S. are HAE patients who offer guidance and support to your HAE patient new to Berinert.
  • Your patient will receive a helping hand from experienced HAE patients who can answer nonmedical questions related to their Berinert therapy.

"They are the most wonderful, compassionate team of people."
- Machelle

*Peer supporters are not healthcare professionals or medical experts. For medical questions, patients should contact their physicians.

Berinert is easy for you to keep it at home or carry with you because it can be stored for up to 30 months and does not require refrigeration.

Convenient Relief is Ready Anytime, Anywhere.

Room-temperature storage means that Berinert is ready to use, easy to transport, and can be kept at home or any place where the temperature is between 36°F and 77°F

Berinert has a 30-month shelf life, which will help minimize your patients’ concerns about maintaining an emergency supply. Specialty and hospital pharmacists can rest assured that the product will not lose potency or require replacement during storage.

"I can take it with me wherever I need it."
- Shari

*Peer supporters are not healthcare professionals or medical experts. For medical questions, patients should contact their physicians.

Save on Co-Pays: The Berinert Co-Pay BENefit™ may cover up to $12,000 of your eligible out-of-pocket expenses per year.

Download Enrollment Form »
continue to
Support Services

Learn about patient and professional support services such as The CSL Behring AssuranceSM, B.E.N. P.A.L.S.® and many other time-saving services for your practice.

Home Why Choose Berinert On-Demand

Important Safety Information

BERINERT®, C1 Esterase Inhibitor (Human), is a plasma-derived concentrate of C1 Esterase Inhibitor (Human), indicated for the treatment of acute abdominal, facial or laryngeal attacks of hereditary angioedema (HAE) in adult and pediatric patients. The safety and efficacy of BERINERT for prophylactic therapy have not been established.

BERINERT is contraindicated in individuals with a history of life-threatening systemic reactions to C1 esterase inhibitor preparations (including anaphylaxis).

Monitor patients for early signs of allergic or hypersensitivity reactions (including hives, generalized urticaria, chest tightness, wheezing, hypotension, and anaphylaxis). If hypersensitivity is suspected, immediately discontinue administration of BERINERT and initiate appropriate treatment. Epinephrine should be immediately available for treatment of acute severe hypersensitivity reactions.

Serious arterial and venous thromboembolic (TE) events have been reported following administration of recommended doses of C1 Esterase Inhibitor (Human) products to patients with HAE. Risk factors may include presence of an indwelling venous catheter/access device; prior history of thrombosis; underlying atherosclerosis; use of oral contraceptives or certain androgens; morbid obesity; and immobility. Weigh benefits/risks before administering to patients with known risk factors for TE events and closely monitor such patients during and after BERINERT administration. TE events also have been reported with C1 Esterase Inhibitor (Human) products when used for unapproved indications at higher than recommended doses.

Appropriately trained patients may self-administer BERINERT upon recognition of an HAE attack. Advise patients to seek medical attention immediately following selfadministration for laryngeal attacks, and to seek medical attention if progress of any attack makes them unable to properly prepare or administer dose of BERINERT.

BERINERT is derived from human plasma. The risk of transmission of infectious agents, including viruses and theoretically, the agents of Creutzfeldt-Jakob Disease (CJD) and its variant form (vCJD), cannot be completely eliminated.

The most serious adverse reaction reported in subjects who received BERINERT in clinical studies was an increase in severity of pain associated with HAE. Dysgeusia was the most common adverse reaction reported in over 4% of subjects and more frequently than in the placebo group.

BERINERT has not been evaluated in pregnant women or nursing mothers, and should be used only if clearly needed. In clinical trials, the half-life of BERINERT was shorter and clearance was faster in children than in adults; the clinical implication of this difference is not known.

Please see full prescribing information for BERINERT, including the patient product information.

CSL Behring
© 2018 CSL Behring. The product information presented on this site is intended for US residents only. BRN/03-13-0059(1)d